News
In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...
Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback